The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

Clinically relevant bleeding requiring medical care occurred in 102 patients in the reduced-dose group compared with 136 patients in the full-dose group (12-months cumulative incidence of 12.1% ...